- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04087499
Potential Role of Acupuncture Treatment in Neuronal and Network Dysfunction in Patients With Vascular Cognitive Impairment
Vascular cognitive impairment (VCI) is a broad dimensional term, ranging from mild cognitive impairment without incapacity on activity of daily living to vascular dementia (VaD), referred to as significant cognitive impairment and decline in function status.
In this three-year project, we aim to evaluate the effects of biochemical data, early clinical variables, neuroimaging results, and intervention of acupuncture treatment on vascular event related cognitive impairment in crossectional analysis and longitudinal follow-up.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Stroke is a common cerebrovascular disease of the central nervous system leading to serious medical complication. It results in a high mortality rate and increased disability rate. Stroke survivors may have long-lasting consequences, including motor dysfunction, sensibility dysfunction, and cognitive impairment]. Cognition is a key component of rehabilitation and recovery; therefore it is associated with poor engagement in rehabilitee and outcomes including increased mortality. As vascular dementia (VaD) is considered the second-most-common type of dementing illness, accounting for a significant proportion of total dementia case, vascular cognitive impairment (VCI) is a broader dimensional term, ranging from mild cognitive impairment without incapacity on activity of daily living to VaD, referred to as significant cognitive impairment and decline in function status.
Acupuncture is an ancient Chinese medical technique in which fine, stainless steel needles are inserted into certain anatomical locations of the body surface to elicit neurohormonal responses of the body system via nerve stimulation. Acupuncture are reported to be probably effective in improving cognitive function in vascular dementia animal models via multiple mechanisms such as anti-apoptosis, antioxidative stress reaction, and metabolism enhancing of glucose and oxygen.
Motor features may not parallel to the cognitive changes, it will serve as the disease progression marker. Unified Parkinson's Disease Rating Scale (UPDRS)-part III scores and NIH Stroke Scale (NIHSS) will be used.
- At Kaohsiung Chang Gung Memorial Hospital, all the patients (n=80) will be included and receive a Standardized Acupuncture intervention; 40 will be treated with regular medication; 40 will be treated with acupuncture and regular medication.
- For acupressure program, all participants are treated in supine position, and a certified TCM physician applied firm pressure (3 to 5 kg of pressure) with fingertips in a circular motion at a speed of 2 circles per second for a duration of one minute per acupoint. The complete process lasts for 8 minutes.
Cognitive function, Motor function, Mood and Sleep will be evaluated at baseline and follow-up period of time at 3 month, 6 month, and 12 month.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Kaohsiung, Taïwan, 83301
- Recrutement
- Kaohsiung Chang Gung Memorial Hospital
-
Contact:
- YaTing Chang
- Numéro de téléphone: 077317123
- E-mail: emily0606@cgmh.org.tw
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
1. Fulfill the diagnostic criteria of vascular cognitive impairment
Exclusion Criteria:
- Systemic inflammatory disease with on-going treatment
- Severe psychiatric disease, such as major depressive disorder or schizophrenia
- Severe traumatic brain injury
- Unable to tolerate exam of brain MRI
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur factice: regular medication treatment
|
acupuncture treatment on selected acupoint
|
|
Expérimental: acupuncture and regular medication treatment
|
acupuncture treatment on selected acupoint
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline sleep quality at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Analogous variables were extracted from actigraphy.
The sleep variables collected were sleep start time, sleep end time, sleep duration, sleep efficiency, and wake after sleep onset time, and the activity variables collected were heart rate activity score,activity amount, and activity intensity
|
3 months, 6 months, 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline neuro-behavioral performances at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Cognitive Abilities Screening Instrument (CASI).
In addition to general cognitive performance, CASI was used to evaluate specific domains, including short-term memory, attention and concentration, abstraction, visual construction, language, and list-generating fluency.
|
3 months, 6 months, 12 months
|
|
Change from baseline motor function (UPDRS) at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Unified Parkinson's Disease Rating Scale (UPDRS)-part III scores for parkinsonian features.
|
3 months, 6 months, 12 months
|
|
Change from baseline motor function (NIHSS) at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
NIH Stroke Scale (NIHSS) score 0-24.
|
3 months, 6 months, 12 months
|
|
Change from baseline continuous motor function at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Physical activity was measured using accelerometers.
|
3 months, 6 months, 12 months
|
|
Change from baseline memory performances at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Verbal memory were evaluated by using Chinese Version Verbal Learning Test (CVVLT).Visual-spatial abilities.
|
3 months, 6 months, 12 months
|
|
Change from baseline executive performances at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Attention and executive function was evaluated by Trail Making Test B.
|
3 months, 6 months, 12 months
|
|
Change from baseline executive performances (Stroop interference test) at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Attention and executive function was evaluated by Stroop interference test.
|
3 months, 6 months, 12 months
|
|
Change from baseline executive performances (calculation) at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
As the calculation ability depends on executive function, calculation ability was evaluated to reflect part of executive function.
|
3 months, 6 months, 12 months
|
|
Change from baseline abstract thinking at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Abstract reasoning was evaluated by using similarities (conceptualization) in frontal assessment battery-Similarities.
|
3 months, 6 months, 12 months
|
|
Change from baseline language performances at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Boston Naming Test were used to evaluate language ability in naming.
|
3 months, 6 months, 12 months
|
|
Change from baseline fluency performances at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
Semantic category fluency.
|
3 months, 6 months, 12 months
|
|
Change from baseline neuropsychiatric symptoms at 3 months, 6 months, 12 months
Délai: 3 months, 6 months, 12 months
|
The neuropsychiatric symptoms of the participants were measured using the Neuropsychiatric Inventory.
|
3 months, 6 months, 12 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: YaTing Chang, MD,PhD, Chang Gung Memorial Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 201802103A3
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .